Skip to main content

Table 4 Drug resistance interpretation for the three superinfection cases

From: Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort

Regime

Case13

Case14

DBC+

 

Resident strain

Superinfecting strain

Resident strain

Superinfecting strain

Resident strain

Superinfecting strain

3TC

HR

HR

PL

S

S

HR

ABC

HR

LL

R

S

S

HR

ATV/r

S

LL

S

S

S

S

AZT

HR

R

HR

LL

PL

HR

D4T

HR

R

HR

PL

LL

HR

DDI

HR

PL

R

S

PL

HR

DLV

S

S

S

S

S

S

DRV/r

S

S

S

S

S

S

EFV

S

S

S

S

S

S

ETR

S

S

S

S

S

S

EVG

S

S

S

S

S

S

FPV/r

S

LL

S

S

S

S

FTC

HR

HR

PL

S

S

HR

IDV/r

S

R

S

S

S

S

LPV/r

S

PL

S

S

S

S

NFV

S

HR

S

S

S

S

NVP

S

S

S

S

S

S

RAL

S

S

S

S

S

S

SQV/r

S

R

S

S

S

S

TDF

R

PL

R

S

PL

LL

TPV/r

S

S

S

S

S

S

  1. Drug resistance (based on http://hivdb.stanford.edu) in the two patients with validated superinfection and the patient suspected for superinfection based on high degenerate base code (DBC) count. Drug resistance interpretation is shown for the samples preceding and following the suspected superinfection event; bullets indicate the drugs administered in the sample interval. In Case 13, resistance against two of the drugs decreased, while resistance against one drug increased concomitant with superinfection; in Case 14, resistance against the current drugs decreased; in the DBC+ case, resistance against both drugs increased. None of the cases involved currently recommended drug regimens. S: Susceptible, PL: Potential low-level resistance, LL: low-level resistance, R: resistance, HR: high resistance.